Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for Executive Function Impairments in Remitted MDD
NCT00985725Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lisdexamfetamine in major depressive disorder (MDD) (2 arms), sponsored by Takeda. Primary endpoint: Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score at 9 weeks. Started Oct 2009; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00985725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985725.